Supplementary Table S1. Primer sequences for mRNA expression analysis by PCR and for ChIP as well as generation of full-length EPC1 promoter construct

Primer name	Sequence
E2F1-fwd	ACCAGGGTTTCCAGAGATGC
E2F1-rev	CACCACACAGACTCCTTCCC
EPC1-fwd	AGCCGATCTTATCCGACCGAA
EPC1-rev	TCCAAGGCCAGTTGCCAGTTT
EZH2-fwd	TATTCAGCGGGGCTCCAAAA
EZH2-rev	TGGATGGCTCTCTTGCGAAA
EED-fwd	TGCTGGAAACCTGGCAAGAT
EED-rev	AGCGCCAAATACTGGCATCA
p27-fwd	TTCATCAAGCAGTGATGTATCTGA
p27-rev	AAGAAGCCTGGCCTCAGAAG
Bax-fwd	CACCAGCTCTGAGCAGATCAT
Bax-rev	GCGGCAATCATCCTCTGCAG
Bim-fwd	TCTGTTGCCAGCCTGCATTGAT
Bim-rev	ATGGGAAAGCCTGCAACCAGAA
Bcl-2-fwd	CGTACAGTTCCACAAAGG
Bcl-2-rev	ATGTGTGTGGAGAGCGTC
BIRC5-fwd	TGCAAAGGAAACCAACAA
BIRC5-rev	TCAATCCATGGCAGCCAG
GAPDH-fwd	GTCATCCCTGAGCTGAAC
GAPDH-rev	CTCCTTGGAGGCCATGTG
EPC1-P1-fwd	GAGCGCACAGTGGAGTTTTA
EPC1-P1-rev	GCCCGAAACGACAGTTTACTC
EPC1-P2-fwd	AGCATCTGCCCCTAATTCAGT
EPC1-P2-rev	CTCACTTTCTCACGCTCGCT
EPC1-P3-fwd	AACCGATGCCACCCATCTAT
EPC1-P3-rev	TCAAAGAGACTGCGGCTTCA
EZH2-P-fwd	CCCTCCACAAATGTGGATCT
EZH2-P-rev	CCAGCCTGAATATGATCACC
EPC1-Prom-fwd	GAGGTACCAAGCTAGTGACAGCTCATATCA
EPC1-Prom-rev	GAAAGCTTCTCAGGCGCAGCAGATACCTCT
p27 ChIP fwd	GGCCTCCCCCGCAGACCAC
p27 ChIP rev	GTTCCGCCACCTCCCCTCGTTCC
Bcl-2 ChIP fwd	CTTCCCAATGAATCAGGAGTCG
Bcl-2 ChIP rev	GCGTCCTGCCTTCATTTATCCA

Supplementary Table S2. Interacting residues of E2F1 and EPC1 in interaction pose A and B

Residues forming H-bond (A: E2F1 & B: EPC1)	Domains of E2F1
Interaction pose A	
A:ARG85:HN - B:GLU49:OE1	Cyclin A/CDK2 binding
A:ARG91:HE - B:ARG36:O	Cyclin A/CDK2 binding
A:ARG91:HH11 - B:GLU93:O	Cyclin A/CDK2 binding
A:ARG91:HH21 - B:SER33:O	Cyclin A/CDK2 binding
A:ARG91:HH22 - B:PHE94:O	Cyclin A/CDK2 binding
A:ARG109:HN - B:ALA84:O	DNA binding
A:GLY110:HN - B:ALA84:O	DNA binding
A:ALA379:HN - B:LYS129:O	Transactivation
B:MET1:HT1 - A:GLU280:O	Marked box
B:ASN35:HD22 - A:GLU354:O	Marked box
B:TYR85:HH - A:ASP436:OD1	Transactivation
B:SER88:HG - A:GLY106:O	Cyclin A/CDK2 binding
Interaction pose B	
A:TYR100:HH - B:ARG461:O	Cyclin A/CDK2 binding
A:SER104:HG - B:GLY460:O	Cyclin A/CDK2 binding
A:ARG111:HH21 - B:TYR412:OH	Cyclin A/CDK2 binding
A:ARG422:HH12 - B:CYS451:O	Transactivation
B:TYR412:HH - A:ASP423:OD1	Transactivation
B:ARG439:HH21 - A:SER121:O	Cyclin A/CDK2 binding
B:ARG450:HH11 - A:GLU419:OE1	Transactivation
B:VAL465:HN - A:GLU103:OE1	Cyclin A/CDK2 binding
B:ARG469:HH12 - A:LEU351:O	Marked box
B:ASN499:HD21 - A:ARG109:O	Cyclin A/CDK2 binding
B:ASN499:HD21 - A:GLY110:O	Cyclin A/CDK2 binding



Supplementary Figure S1 related to Figure 4. EPC1 suppresses cisplatin (cDDP) induced apoptosis. (**A**) Representative photomicrographs of Hoechst 33342 stained (1 µg/ml) SK-Mel-147 cells expressing indicated shRNAs in the presence or absence of cDDP (30 µM). Cells exposed to cDDP exhibit characteristic chromatin condensation. (**B**) The bar graph represents the percentages of apoptotic cells relative to the sh.EPC1#1/+cDDP group. Quantification of apoptosis was determined by counting the number of apoptotic cells from four randomly chosen fields of view per condition with a minimum number of 500 cells scored in each. Data are presented as the mean with standard deviation in an experiment representative of several independent others. Asterisks indicate P values of <0.01.